Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27952590 | 0.86 | LMNA (0.50) | POLBMAPTKMT2ALMNAALDH1A1 | |
| SCHEMBL3318354 | 0.83 | LMNA (0.53) | POLBMAPTKMT2ALMNANPC1 | |
| SCHEMBL5468538 | 0.82 | ALDH1A1 (0.53) | POLBMAPTKMT2ALMNANPC1 | |
| SCHEMBL3979515 | 0.82 | LMNA (0.52) | POLBMAPTKMT2ALMNANPC1 | |
| SCHEMBL3696586 | 0.82 | LMNA (0.64) | POLBMAPTKMT2ALMNANPC1 | |
| SCHEMBL20521839 | 0.80 | LMNA (0.50) | POLBMAPTKMT2ALMNANPC1 | |
| SCHEMBL15671912 | 0.80 | LMNA (0.50) | POLBMAPTKMT2ALMNANPC1 | |
| SCHEMBL29705211 | 0.80 | LMNA (0.50) | POLBMAPTKMT2ALMNANPC1 | |
| SCHEMBL15671945 | 0.80 | LMNA (0.50) | POLBMAPTKMT2ALMNANPC1 | |
| SCHEMBL11283967 | 0.79 | POLB (0.62) | POLBMAPTKMT2ALMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| EP-2707367-B1 | METHODS FOR PREPARING NAPHTHYRIDINES | BIONOMICS LTD (AU) | 2019-10-09 | — | — | EP | disclosed |
| EP-2707367-B1 | METHODS FOR PREPARING NAPHTHYRIDINES | BIONOMICS LTD (AU) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019109150-A1 | METHODS OF TREATING AGITATION | BIONOMICS LIMITED (AU) | 2019-06-13 | — | — | WO | disclosed |
| US-10233181-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| US-10233181-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| EP-2074123-B1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LTD (AU) | 2012-12-05 | — | — | EP | disclosed |
| EP-2074123-B1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LTD (AU) | 2012-12-05 | — | — | EP | disclosed |
| WO-2012151640-A1 | METHODS FOR PREPARING NAPHTHYRIDINES | BIONOMICS LIMITED (AU) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012151640-A1 | METHODS FOR PREPARING NAPHTHYRIDINES | BIONOMICS LIMITED (AU) | 2012-11-15 | — | — | WO | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| WO-2012116410-A1 | METHODS OF TREATING A DISEASE OR CONDITION OF THE CENTRAL NERVOUS SYSTEM | BIONOMICS LIMITED (AU) | 2012-09-07 | — | — | WO | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| WO-2008046135-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233181-B2 | Anxiolytic compounds | GABBR1, GABRA6, SLC18A2 | POLB 3948/4885MAPT 1130/4885KMT2A 2335/4885 |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | POLB 4582/4885MAPT 1438/4885KMT2A 2188/4885 |
| US-10954231-B2 | Anxiolytic compounds | GABRA6, GABRA2, GABRA5 | POLB 3815/4885MAPT 929/4885KMT2A 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.